Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). - Wikidata - wikimedia - TriplyDB

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

http://www.wikidata.org/entity/Q31094492

about

Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study.β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.Novel treatment approaches in hypertensive type 2 diabetic patients Type of β-blocker use among patients with versus without diabetes after myocardial infarction Alpha-receptor blockade improves muscle perfusion and glucose uptake in heart failure.Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease The effects of comorbidity on the benefits and harms of treatment for chronic disease: a systematic review.Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study.Recognition of incident diabetes mellitus during an acute myocardial infarction Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a long-term special survey.Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey Carvedilol in the treatment of elderly patients with chronic heart failure.A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus.Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.Personalized vascular medicine: individualizing drug therapy Diabetes, left ventricular systolic dysfunction, and chronic heart failure.Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.Beta-blocker use for the stages of heart failure.Effects of Beta-Blocker Titration on Glucose Homeostasis in Heart Failure Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension?Role of carvedilol controlled-release in cardiovascular disease.Glucose and insulin abnormalities in patients with heart failure.Lipid effects of antihypertensive medications.Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.Choice of anti-hypertensive agents in diabetic subjects.Cardiogenic diabetes.Novel insight into the dangerous connection between diabetes and heart failure.Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.Body mass index is closely correlated to incident diabetes in patients with heart failure or myocardial infarction.Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus.Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

P2860

Q27003819-38CAE755-1230-4752-8B1A-0BA8AA14F88A Q28068618-FB8E4174-1042-4484-820E-7B2C7F0DE978 Q33561456-5E38F1B1-7975-46E7-8992-892D1CDE1517 Q33945028-47201EBB-F2A0-479F-91EA-C9FE261AB405 Q34019246-3B71282D-C363-4B4C-BF97-5E1AAD190087 Q34023579-F5C115D8-C9F6-4318-B808-19099EE5D058 Q34117758-78ABA389-8BAD-493F-914E-072F3EBF09CC Q34308244-89EF4267-E947-4C83-B1E4-C78992718AB9 Q35027981-0BD05892-1392-48AB-9E2E-AF33C60173C4 Q35427801-83895E6D-36FF-42BA-9322-CA2BD92075C7 Q35540707-2805F9F6-0511-466A-836E-30F8E4BC23E7 Q35629691-D6CDB233-6504-48FA-B58C-2580EAB36A1D Q36648994-B521168A-8B5B-40DF-8F9B-CD2F54CABE78 Q36650008-647BA776-B5B4-4BC4-AB78-79B1F39D6D81 Q36892905-E646CAEC-237B-4A0D-AD2C-547120C4871C Q37031357-29C2D1FF-F55A-49E0-80F7-2DEE0FD2C625 Q37076468-87C056D4-8B9D-4C4E-A86C-D77C2CF3D2F5 Q37142852-45C5DB3B-4FA8-48BF-BEA1-690AFD7B4ED0 Q37143034-BEB00A6C-464C-417B-8315-A71DE6D6E4CE Q37145670-8DD3A202-EEE5-4DCD-923B-FB5E05867A4C Q37233317-FDA402B3-69DF-4150-84E6-F3EE8C9AB023 Q37285564-294DDE9C-0103-49C4-B7E8-E619227F2954 Q37299734-14E79BDF-D084-4D68-93DB-1195103CBC93 Q37380495-87C66773-36CE-4936-9FC4-957B2984C997 Q37472042-FD057A04-4FB9-496C-B79E-4D49BAA70ACA Q37801130-23D33138-5297-40C6-861D-56FC3A012F1F Q37950846-D753CB1C-3A77-4673-B5B4-04BDCF791B4B Q37965654-C73E7FA8-E7A5-4E97-9E40-960AC24E5DD2 Q38118047-6C1673D9-EB29-4982-A798-39324B1E4C79 Q38156709-CA3F0739-70E7-43EA-B43E-C5DAD5D7E879 Q38806574-EC2F96D6-8A02-4C1B-9468-13E668413772 Q39360754-DF0BC6B3-65BF-46E7-A333-23F1940B2476 Q43419507-DE10E09A-41CE-491B-B048-2F32B46D05F1 Q43929425-0743967A-26AC-4974-B563-112702FBEA68 Q43932153-05D22F8F-6EDD-4313-852E-93A91470DA3E Q44477225-0C253177-D955-46A8-B618-ACA8AF331057 Q46138106-67FE8863-93EE-4A79-9805-87E76CB9B932 Q54235357-F6AA22B7-A4E1-4BB1-953E-05D41A13976A Q55078568-477A2FBE-6F1B-4A11-ADB5-DCD13B34491C Q56970710-1173D00E-5F90-4C38-89AB-72D32115A0B2

P2860

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

http://www.wikidata.org/entity/Q31094492

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@ast

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@en

type

label

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@ast

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@en

prefLabel

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@ast

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@en

P1433

Q31094492-740052F0-A010-4AAF-877F-E8CDBC55C96C

P1476

Q31094492-B8BC8D2D-5550-4DE8-8AD3-A1E9B7A3FCDF

P2093

Q31094492-0BB098EF-FFDD-47B5-822D-1D5DBAF0F991

Q31094492-13B357F3-F4E4-42DF-9FCA-AA84D1B2EA5C

Q31094492-199A18E6-7A09-40DD-B70F-08A7CBD7E047

Q31094492-2F322D1D-957B-4A1E-AD0D-DFE87616DFC3

Q31094492-50F0445D-CFF3-4352-9B75-B225BAC456B3

Q31094492-AECB2DFE-0E72-43CA-AF30-B6D17EE9AC44

Q31094492-B8115377-C8DA-4B5D-8565-B1598C3C869B

Q31094492-DBE2AAE8-869D-4587-8203-04D0477074B9

Q31094492-E2E9A010-02DF-42F8-8100-996891C91D8D

P2860

Q31094492-036B82C2-F2B5-4D27-9AD7-65EAA33CD476

Q31094492-0503F620-0B49-4B41-8DCB-C4335735B97B

Q31094492-12E3E05E-4DBA-47B4-A41D-04346D015A77

Q31094492-1765472A-7D32-473E-8517-F8266DD1A66E

Q31094492-1E8CEA35-7060-4222-8CF6-86FC46D51603

Q31094492-2F840221-1B62-43B0-9611-180309713F6C

Q31094492-4A7465D2-A1D9-4024-B59B-52AB207440CA

Q31094492-4BAB5FEB-3313-4626-8D05-D7F02EA84F8C

Q31094492-5CBE634D-4ABF-437E-A51E-6E18FA1961E6

Q31094492-6E74E6DD-9757-4E0F-B216-F977DB216E67

P304

Q31094492-5928B791-DF40-44A2-8117-70AFFF5F1D7B

P31

Q31094492-3F91C9C7-601D-440C-B92F-CA1F6CE25835

P356

Q31094492-6609802A-062D-435F-91A9-459B340ED760

P407

Q31094492-BF11D745-E97B-4676-BB20-15545D8360DD

P433

Q31094492-3DBD260D-72AB-484A-9BA3-5F73F70BF1B2

P478

Q31094492-468F73AF-0FC1-4539-B714-159FBE03A334

P50

Q31094492-3BE2816F-5D51-48AB-9D96-D7C2815A9EE0

Q31094492-49AF6D4C-E6CA-423E-AFF5-FECB3E9D62AC

Q31094492-B5EEEAA2-0D4E-4BD9-8EE2-83BAB2149C2C

P577

Q31094492-5DCF6FAA-70DF-4807-A36B-0EF548CCEE29

P5875

Q31094492-F17746D3-24C6-4BAA-8307-F0EF8F91586C

P698

Q31094492-3464F32E-6533-47CD-ACDB-943141026FF3

P932

Q31094492-EDBB2A5D-7736-4D8A-B19B-A3242E99098A

P356

HRT.2006.092379

P1433

P1476

Effects of metoprolol and carv ...... prolol European Trial (COMET).

@en

P2093

Andrea Di Lenarda

http://www.w3.org/2001/XMLSchema#string

Andrew Charlesworth

http://www.w3.org/2001/XMLSchema#string

Armin Scherhag

http://www.w3.org/2001/XMLSchema#string

COMET investigators

http://www.w3.org/2001/XMLSchema#string

John G F Cleland

http://www.w3.org/2001/XMLSchema#string

Mary Ann Lukas

http://www.w3.org/2001/XMLSchema#string

Philip A Poole-Wilson

http://www.w3.org/2001/XMLSchema#string

Phillip Spark

http://www.w3.org/2001/XMLSchema#string

Willem J Remme

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies.

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.

Diabetes mellitus and congestive heart failure. Further knowledge needed.

Effect of carvedilol on survival in severe chronic heart failure.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

beta-Blocker therapy in heart failure: scientific review.

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.

Expert consensus document on beta-adrenergic receptor blockers.

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.

P304

968-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.2006.092379

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Christian Torp-Pedersen

P577

2007-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6566173

http://www.w3.org/2001/XMLSchema#string

P698

17237130

http://www.w3.org/2001/XMLSchema#string

P932

1994413

http://www.w3.org/2001/XMLSchema#string